Citizens Jmp Issues Positive Forecast for Sabra Healthcare REIT (NASDAQ:SBRA) Stock Price

Sabra Healthcare REIT (NASDAQ:SBRA) had its price objective boosted by Citizens Jmp from $23.00 to $25.00 in a research report released on Wednesday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the real estate investment trust’s stock.

Several other brokerages also recently commented on SBRA. Raymond James Financial assumed coverage on shares of Sabra Healthcare REIT in a report on Wednesday, June 17th. They set an “underperform” rating on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sabra Healthcare REIT in a research report on Wednesday. Weiss Ratings downgraded Sabra Healthcare REIT from a “buy (b+)” rating to a “buy (b)” rating in a report on Thursday, June 4th. Citigroup reiterated a “market outperform” rating on shares of Sabra Healthcare REIT in a report on Wednesday. Finally, Barclays started coverage on shares of Sabra Healthcare REIT in a report on Tuesday, July 7th. They set an “overweight” rating and a $21.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.25.

Sabra Healthcare REIT Price Performance

NASDAQ:SBRA opened at $21.98 on Wednesday. The firm has a market capitalization of $5.54 billion, a price-to-earnings ratio of 34.89, a PEG ratio of 1.64 and a beta of 0.65. The company has a debt-to-equity ratio of 0.96, a current ratio of 4.72 and a quick ratio of 4.72. The business has a 50 day simple moving average of $19.63 and a 200-day simple moving average of $19.80. Sabra Healthcare REIT has a 1 year low of $17.17 and a 1 year high of $22.55.

Sabra Healthcare REIT (NASDAQ:SBRA) last released its quarterly earnings results on Wednesday, April 29th. The real estate investment trust reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. The company had revenue of $211.74 million for the quarter, compared to analyst estimates of $209.20 million. Sabra Healthcare REIT had a return on equity of 5.60% and a net margin of 19.22%.Sabra Healthcare REIT’s quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.37 EPS. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. Equities analysts forecast that Sabra Healthcare REIT will post 1.5 EPS for the current year.

Sabra Healthcare REIT Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Friday, May 15th were paid a $0.30 dividend. This represents a $1.20 annualized dividend and a yield of 5.5%. The ex-dividend date was Friday, May 15th. Sabra Healthcare REIT’s payout ratio is 190.48%.

Institutional Trading of Sabra Healthcare REIT

Several hedge funds have recently modified their holdings of SBRA. Rothschild Investment LLC raised its stake in shares of Sabra Healthcare REIT by 164.6% during the 4th quarter. Rothschild Investment LLC now owns 1,429 shares of the real estate investment trust’s stock worth $27,000 after acquiring an additional 889 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Sabra Healthcare REIT by 97.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the real estate investment trust’s stock worth $27,000 after purchasing an additional 714 shares in the last quarter. Strengthening Families & Communities LLC purchased a new stake in shares of Sabra Healthcare REIT during the 4th quarter valued at $29,000. Versant Capital Management Inc boosted its position in shares of Sabra Healthcare REIT by 70.0% in the 2nd quarter. Versant Capital Management Inc now owns 1,465 shares of the real estate investment trust’s stock worth $29,000 after purchasing an additional 603 shares in the last quarter. Finally, Danske Bank A S purchased a new position in Sabra Healthcare REIT during the 3rd quarter worth $30,000. 99.40% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Sabra Healthcare REIT

Here are the key news stories impacting Sabra Healthcare REIT this week:

• Positive Sentiment: Truist Financial raised its price target on Sabra Healthcare REIT from $22 to $24 and reiterated a buy rating, signaling confidence in further upside. Benzinga
• Positive Sentiment: Citizens JMP lifted its price target from $23 to $25 and maintained a market outperform rating, suggesting analysts see additional room for the stock to climb. Benzinga
• Positive Sentiment: Sabra increased FY 2026 EPS guidance to $1.53-$1.55, above the consensus estimate of $1.50, which supports the case for stronger-than-expected earnings. Business Wire
• Positive Sentiment: The company announced a major portfolio reshaping, including plans to re-tenant properties previously leased to Avamere, which may improve occupancy stability and operational quality over time. TipRanks
• Neutral Sentiment: Zacks noted SBRA was a strong recent mover on heavy volume, but also warned that recent FFO estimate revisions could limit near-term follow-through. Zacks

Sabra Healthcare REIT Company Profile

Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.